Functional Changes after Pancreatoduodenectomy: Diagnosis and Treatment

T.C. Khe Tran¹  Jan J.B. van Lanschot¹  Marco J. Bruno²  Casper H.J. van Eijck¹

Departments of ¹Surgery and ²Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands

Key Words
Pancreatoduodenectomy  Functional changes  Delayed gastric emptying  Endocrine and exocrine pancreatic insufficiency  Enteric-coated capsules  Quality of life

Abstract
Relatively little is known about the gastrointestinal function after recovery of a pancreatoduodenectomy. This review focuses on the functional changes of the stomach, duodenum and pancreas that occur after pancreatoduodenectomy. Although the mortality in relation to pancreatoduodenectomy has decreased over the years, it remains associated with considerable morbidity, which occurs in 40–60% of patients. Physical complaints early after the operation are often caused by motility disorders, in particular delayed gastric emptying, which occurs in up to 40% of patients. During longer follow-up of these patients the occurrence of endocrine and exocrine pancreatic insufficiency becomes more predominant. Diabetes mellitus develops in 20–50% of patients after a pancreatic resection (pancreatogenic diabetes). The main presenting symptoms of exocrine insufficiency are weight loss and steatorrhea. Its presence is suspected on clinical ground and can be supported by fecal elastase-1 measurement. Exocrine insufficiency can be compensated with oral enteric-coated enzyme supplements. The quality of life issue will be addressed as an important outcome measurement after pancreatoduodenectomy. Furthermore, the functional changes after pancreatoduodenectomy are described in detail with suggestions for diagnosis and treatment.

Introduction
Surgery is the cornerstone of treatment with curative intention for patients with tumors of the pancreatic head and the periampullar region. Radical resection by means of pancreatoduodenectomy offers the only chance for cure. Partial pancreatoduodenectomy was introduced in the beginning of the 20th century by Codivilla and Kausch. A modification of the classical partial pancreatoduodenectomy as popularized by Whipple et al. [1] is the pylorus-preserving pancreatoduodenectomy (PPPD), first described by Watson [2] in 1944. Preserving the pylorus is thought to have various advantages, such as simplification of the operation and improvement of postoperative gastrointestinal function without any negative oncological consequences for the patient [3]. To date, three randomized studies compared the classic Whipple’s operation with PPPD. Two relatively small studies reported that the pylorus-preserving procedure was associated with shorter operation time, less blood loss, less blood transfusion and a lower morbidity rate in comparison to the classic Whipple procedure [4, 5]. In contrast, our own
randomized multicenter study [6] found no difference between both procedures in operation time, blood loss, delayed gastric emptying, hospitalization time, or overall survival rate.

In spite of the still relatively high morbidity resulting from the extensive and invasive surgical procedure, pancreatoduodenectomy is increasingly being performed. This is partly because of a considerable reduction in perioperative mortality. In high-volume centers, a mortality rate of less than 2% has been reported [7–12]. Because of these advances, the assessment and improvement of short- and long-term postoperative quality of life have become important topics. Many publications have reported on quality of life issues after pancreatoduodenectomy [2, 13–18]. However, relatively little is known about the gastrointestinal function after recovery of a pancreatoduodenectomy.

This review focuses on the functional changes of the stomach, duodenum and pancreas that occur after pancreatoduodenectomy. The various factors and mechanisms that are involved will be described with recommendations for diagnosis and treatment.

In table 1, a summary is given of the functional changes of the stomach, duodenum and pancreas after pancreatoduodenectomy.

**Table 1. Functional changes of the stomach, duodenum and pancreas after pancreatoduodenectomy**

<table>
<thead>
<tr>
<th>Functional changes</th>
<th>Incidence</th>
<th>Presentation</th>
<th>Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delayed gastric emptying</td>
<td>15–40%</td>
<td>nasogastric tube &gt;10 days</td>
<td>gastric emptying scintigraphy</td>
<td>recovery &lt;6 months erythromycin®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>inability to tolerate a regular diet ≥14th day p.o.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duodenum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>↓ Pancreas-stimulating hormones</td>
<td>100%</td>
<td>altered digestion process</td>
<td>failure to thrive</td>
<td>symptomatic proton pump inhibitors</td>
</tr>
<tr>
<td>Peptic ulcer formation</td>
<td>&lt;5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>20–40%</td>
<td>hyperglycemia</td>
<td>↓ glucagon</td>
<td>hormonal regulation</td>
</tr>
<tr>
<td>Exocrine insufficiency</td>
<td>unknown</td>
<td>algorithm figure 1</td>
<td>↑ insulin insensitivity</td>
<td>figure 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Changes in Gastric Function**

Delayed gastric emptying (DGE) is a leading cause of morbidity after pancreatoduodenectomy, occurring early after the surgical procedure with an estimated incidence between 15 and 40%. DGE is defined as gastric stasis requiring nasogastric intubation for ten days or more or the inability to tolerate a regular diet on the 14th postoperative day [19]. Whether or not the pylorus is preserved does not seem to have a great impact in the occurrence of delayed gastric emptying [6]. There is a decrease in the subjective perception of the occurrence of belching and nausea after Whipple’s operation due to the absence of mechanoreceptors as a result of the partial stomach resection [20]. Other causes of DGE after pancreatoduodenectomy are the presence of peritonitis as a result of postoperative complications such as intra-abdominal abscesses, leakage of the pancreatojejunosatomy, ischemia of the antropyloric muscles and reoperation [21, 22]. Objective quantification of DGE is difficult. In daily practice, gastric scintigraphy is the preferred method to determine DGE. For this purpose, technetium (20 MBq ⁹⁹ᵐ Tc-pertechnetate) labeled semi-solids or a technetium (20 MBq ⁹⁹ᵐ Hmp ⁹⁹ Tc-hepatate) labeled pancake are used. Normal half-emptying time varies between 38 and 83 min after intake. In general, this investigation is considered too time-consuming and too much of a burden for patients in the early postoperative phase and a presumptive diagnosis is usually made on clinical grounds.

Naritomi et al. [23] showed that a low serum level of motilin delays gastric passage in these patients. In a randomized, placebo-controlled study of 118 consecutive patients undergoing a pancreatoduodenectomy, Yeo et al. [24] have shown that the administration of erythromycin, which has not only antimicrobial but also prokinetic activity, stimulates gastric evacuation. They found a significantly reduced need to reinsert a nasogastric tube and a
significantly reduced retention of liquids in the group of patients that was treated with erythromycin. Besides erythromycin, most commonly used prokinetics are metoclopramide, domperidon and cisapride with variable clinical relief of symptoms. The value of new prokinetics, including mosapride citrate (a selective agonist for 5-hydroxytryptamine-4 receptors), itopride hydrochloride (a benzamide derivative with both dopamin D2 receptor antagonism and acetylcholinesterase inhibition) and GM-611 (an erythromycin-derived motilin agonist) has not yet been fully investigated and therefore these drugs are not yet regularly used in clinical practice. In general, the gastric emptying function gradually recovers spontaneously to the preoperative level by 6 months after PPPD.

**Changes in Duodenal Function**

With the resection of the largest part of the duodenum, the major digestive processes are disturbed and the delicately controlled digestive chain between the stomach, duodenum and pancreaticobiliary secretions is disrupted. A reduced production of pancreas-stimulating hormones such as gastrin, cholecystokinin (CCK) and secretin leads to an inadequate pancreatic secretion of bicarbonate. As a result, the gastric content is not neutralized to an optimal pH. Furthermore, a reduced production of enterokinase by the duodenum leads to an inadequate activation of pancreatic proteolytic, amylolytic and lipolytic enzymes.

As mentioned before, resection of the pancreatic head and duodenum results in a decrease in pancreas bicarbonate secretion and inadequate gastric acid neutralization. Excretion of this bicarbonate-poor fluid in the remnant of the duodenum stimulates the development of ulcers. However, peptic ulcers occur in less than 5% of patients after pancreatic surgery [25]. A possible explanation could be the frequent use of octreotide and proton-pump inhibitors postoperatively, although controversies remain regarding their use after a pancreatoduodenectomy.

**Changes in Endocrine Pancreatic Function**

The more extended the resection of the pancreas, the greater the risk of endocrine (and exocrine) pancreatic insufficiency.

The incidence of diabetes mellitus after a pancreatic resection varies between 20 and 50% [26], with some patients already suffering from diabetes preoperatively and a number of patients developing diabetes de novo.

Controversy remains whether diabetes is a risk factor for the development of pancreatic cancer or whether pancreatic cancer causes diabetes. There are compelling data that long-standing diabetes might increase the risk of pancreatic cancer [27–30]. However, in simple cross-sectional studies (recent-onset) diabetes is frequently diagnosed in combination with pancreatic cancer. This is an argument against preexisting diabetes mellitus being a risk factor for pancreatic cancer. Probably, these observations can neither be fully explained by destruction of the endocrine pancreas, but rather seem to be partly the result of a remote effect of the tumor causing impaired glucose metabolism. An interesting clinical observation is the fact that in some patients the diabetes disappears postoperatively [31].

On the other hand, preoperative obstruction of the pancreatic duct is associated with the development of diabetes mellitus as a result of destruction of the parenchyma [32]. In our own experience [33] patients with an iatrogenic pancreatic duct occlusion during a pancreatoduodenectomy develop significantly more diabetes mellitus in comparison to those who had a pancreaticojejunal anastomosis.

The type of glucose intolerance which results from pancreatic resection is termed pancreatogenic diabetes. It is associated with features distinct from both type I (insulin-dependent) and type II (insulin-independent, or adult-onset) diabetes [34].

Hepatic insulin resistance with persistent endogenous glucose production and enhanced peripheral insulin sensitivity results in a brittle form of diabetes, which can be difficult to manage. Surprisingly, pancreatogenic diabetes is characterized by a decrease in hepatic insulin receptor availability and an increase in peripheral insulin receptor availability [35]. This paradoxical effect is probably due to the concurrent deficiency in pancreatic polypeptide and renders the liver resistant to the suppressant effects of insulin on hepatic glucose production. The result of increased hepatic glucagon responsiveness and diminished hepatic insulin responsiveness is elevated (or unsuppressed) endogenous glucose production, which in turn results in hyperglycemia together with an enhanced hypoglycemic response to exogenous insulin in patients with pancreatogenic diabetes.
Assessment of Endocrine Pancreatic Function

Diabetes mellitus is defined as a fasting glucose concentration $\geq 7.0 \text{ mmol/l}$ or a random glucose value $\geq 11 \text{ mmol/l}$ [36] or a GTT (glucose tolerance test) level $\geq 11 \text{ mmol/l}$ after 2 h.

Treatment of Endocrine Pancreatic Insufficiency

Usually, the treatment of patients with diabetes starts with diet, weight reduction, and exercise. After a pancreatic resection most patients already suffer from maldigestion problems.

Patients with persistent hyperglycemia are often started on one or more oral hypoglycemic drugs. Insulin is added if target level of glucose is not attained. Patients with pancreatogenic diabetes behave differently compared to other diabetics with respect to insulin therapy. These ‘brittle diabetics’ may become unpredictably hypoglycemic during maintenance insulin therapy, unrelated to meals or exercise. The need for insulin depends upon the delicate balance between insulin secretion, insulin resistance and glucagon responsiveness.

Changes in Exocrine Pancreatic Function

From the scant data that are available to date, it is difficult to provide an overview of the risk of exocrine insufficiency and the success or failure rate of supplementation therapy. The pathophysiology is complex and comprises factors such as preoperative exocrine pancreatic function and the chosen surgical procedure of resection and restoration of gastrointestinal tract continuity.

In general, the functional reserve of exocrine pancreatic functions ensures that insufficiency occurs only during the course of illness. Up to 90–95% of the pancreatic enzyme output may be lost before clinical signs of exocrine insufficiency develop [37].

The most frequently described change in exocrine pancreatic function after pancreateoduodenectomy is reduced digestion of fat which leads to weight loss, nutrient deficiency and subjective complaints consistent with steatorrhea [38]. It is extremely difficult to appreciate and unravel the impact of each individual factor that contributes to the postsurgical maldigestion.

Most of the data on exocrine pancreatic insufficiency after pancreatic surgery arise from studies in patients with chronic pancreatitis. This group of patients is known to develop exocrine pancreatic insufficiency frequently in the course of their illness due to destruction of acinar cells with replacement of the parenchyma by fibrous tissue. Deterioration of the exocrine function often occurs after pancreatic surgery, partly depending on the extensiveness of resection.

Another important factor regarding the exocrine function is whether the pancreatectoduodenectomy is combined with a partial resection of the stomach. First of all there is an inadequate grinding of food particles. Secondly, a reduced secretion of secretin and CCK results in a reduced production of bicarbonate-rich fluid and digestive enzymes, such as amylase, lipase and trypsinogen, which are important for the continuation of the digestion. Finally, the resection of the pancreatic parenchyma also contributes to a decreased production of pancreatic juices, leading to maldigestion and malabsorption of nutrients postoperatively.

Although compensatory hypertrophy of the pancreatic remnant with increased enzyme production has been observed in animal research, this is hardly ever sufficient to compensate for the induced exocrine insufficiency in the clinical setting.

The type of reconstruction after pancreatectoduodenectomy also appears to affect the occurrence of exocrine loss of function. In some studies [39] a pancreategastrectomy is described to cause further deterioration of the exocrine insufficiency as a result of accelerated inactivation of pancreatic enzymes by gastric juices.

Assessment of Exocrine Pancreatic Function

A number of different exocrine pancreatic function tests are available [40]. The secretin-cerulein intubation test is often used as the ‘gold standard’. This test involves the collection of gastric juices after intravenous administration of secretin and measurement of luminal bicarbonate and protein levels. However, it is difficult or even impossible to perform postoperatively. Much less elaborate are indirect nonintubation function tests with administration of a pancreatic enzyme supplement and the measurement of the enzymatic breakdown of intraluminally administered products. The most widely used tests for this purpose are the bettirome or N-benzoyl-L-tyrosyl-p-aminobenzoic acid test (BT-PABA/PAS test) and the pancreolauryl (fluorescein dilaurate) test. In the bettirome test, bettirome is broken down by chymotripsin into p-aminobenzoic acid and aminobenzoate acid, which is absorbed and secreted by the urine. However,
false-positive test results (i.e. exocrine pancreatic insufficiency is falsely diagnosed) may occur in cases of poor absorption due to intestinal resection, delayed gastric emptying or rapid intestinal transit. In the pancreolauryl test, fluorescein dilaurate is administered, which is also absorbed and secreted by the urine. Preexisting liver disease, renal insufficiency and malabsorption syndromes can induce false-positive results.

For clinical practice, the fecal elastase-1 test is an effective test for the evaluation of exocrine pancreatic insufficiency [41–44]. This test has a number of advantages. First, the enzyme is not degraded during intestinal transport; secondly, elastase is concentrated in the feces, and, finally, the enzyme is easily detected by means of an ELISA test. Especially during the initial phase of exocrine pancreatic insufficiency this test shows high sensitivity and specificity. Another advantage of this test is the fact that the results are not affected by the use of enzyme supplementation therapy.

The cholesteryl $[^{14}C]$octanoate breath test is also a suitable indirect test for this purpose [45, 46]. The test is based on the intraluminal hydrolysis of cholesteryl-$[^{14}C]$octanoate by pancreatic cholesterol esterase and the subsequent absorption and rapid metabolism of $^{14}C$-octanoic acid to $^{14}CO_2$. Measurement of $^{14}CO_2$ in breath allows an indirect estimation of intraluminal hydrolytic activity and its time course. Only pancreas-specific enzyme activity is measured since intraluminal activity of cholesterol esterase is of pancreatic origin only.

**Treatment of Exocrine Pancreatic Insufficiency**

In clinical practice, it is recommended to supplement pancreas enzymes after any form of pancreatic resection. In several studies [47–52] the enteric-coated (mini-)microspheres are generally the preferred pharmacological formulation of pancreatic enzymes. The coating with a pH sensitive polyacryl acid layer, which only dissolves at
a pH level >5.5, maintains the enzyme integrity in the stomach and therefore improves the efficacy of the enzyme supplements. For this reason, the use of a proton pump inhibitor postoperatively also helps to increase the pH in the proximal small intestine, aiding to achieve a rapid and proximal release of pancreatic enzymes from the enteric coat. The coating also masks the unpleasant taste of these enzymes. However, one should keep in mind that in patients who already suffer from impaired digestion due to the partial gastric resection, the duodenum resection and the jejunal reconstruction, the enzyme release from these enteric-coated preparations will be too slow and therefore the efficacy will decrease. Therefore, in order to obtain an optimal therapeutic effect, it is recommended to administrate oral enzymes just after the meals, or even better, distributed along with meals [53].

In figure 1 an algorithm is suggested for diagnosis and treatment of pancreatic exocrine insufficiency.

**Proposal for Diagnostic and Therapeutic Approach of Pancreatic Insufficiency**

In all patients with a condition involving the pancreas, we recommend a fasting glucose level and fecal elastase-1 determination at onset. If the results are abnormal one can start treatment with hormonal regulation and enzyme supplementation.

Apart from decreased insulin production, the increase in insulin insensitivity combined with the decrease in glucagon production may play an important part in these patients. Therefore, postoperative monitoring of the glucose level is of great importance in order to treat endocrine pancreatic insufficiency adequately.

Enzyme supplementation can be started directly after resuming oral intake postoperatively. The recommended start doses of pancreatine capsules are 25,000 to 50,000 IU lipase during a main meal and 10,000 to 25,000 IU lipase during in-between snacks. For an optimal mixture of food and enzymes, the ingestion of enzymes should be divided over the meal. The efficacy of treatment is evaluated by means of repeated measurements of body weight and history takings of steatorrhea-associated complaints.

Persistent weight loss and steatorrhea are indications of an inadequate compensation of the exocrine pancreatic insufficiency. In case of an insufficient treatment response, the dosis should be increased and/or a proton-pump inhibitor should be started. In treatment-resistant cases other diagnosis such as celiac disease or bacterial overgrowth should be considered. The efficacy of treatment is evaluated by means of repeated measurements of body weight and history takings of steatorrhea-associated complaints. The cholesteryl [14C]octanotate breath test can be used for monitoring.

**Conclusion**

Motility disorders and endocrine and exocrine pancreatic insufficiency are frequently encountered after pancreatectoduodenectomies. The resulting symptoms have a substantial impact on the patient’s quality of life. Now that the postoperative mortality after pancreatectoduodenectomy has substantially decreased, more attention should be focussed on the diagnosis and treatment of the functional consequences after pancreatectoduodenectomy. For this purpose, we have indicated a practical guideline.
T.C. Khe Tran, MD
Currently: Gastrointestinal and Transplant Surgeon, Department of Surgery, Erasmus MC, Rotterdam, The Netherlands
Fellowship Gastrointestinal Surgery: Erasmus MC, Rotterdam, The Netherlands
Residency: University Hospital-St Radboud, Nijmegen, The Netherlands

Jan J.B. van Lanschot, MD, PhD
Currently: Professor and Chairman, Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.
Previously: Professor of Surgical Oncology, AMC, Amsterdam, The Netherlands
Research Fellowship: Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass., USA
Residency: University Hospital-Dijkzigt, Rotterdam, The Netherlands

Marco J. Bruno, MD, PhD
Marco J. Bruno was trained at the Department of Gastroenterology and Hepatology at the Academic Medical Center (AMC) in Amsterdam under the supervision of Guido Tytgat. His PhD thesis focused on the efficacy of enzyme replacement therapy in exocrine pancreatic insufficiency. After his training, he continued his career as a staff member specializing in the area of hepatopancreato-biliary diseases and advanced interventional endoscopy, including ERCP and EUS. In March 2008, he changed positions and moved to the Department of Gastroenterology and Hepatology of the Erasmus Medical Center (EMC) in Rotterdam. He is Director of Endoscopy. His clinical and research activities focus on gastrointestinal oncology and interventional endoscopy, and he has a special interest in pancreatic diseases. He has published in many peer-reviewed medical journals, has been a speaker at numerous international symposia and congresses, and has contributed to various international live endoscopy workshops.
Casper H.J. van Eijck, MD, PhD

Casper H.J. van Eijck was born January 9th 1957 in Rotterdam, The Netherlands. He studied medicine at the Erasmus University from 1977 till 1984. He started his surgical residency in 1985 in at the Leyenburg Hospital in The Hague and after 4 years he finished his residency at the Erasmus Medical Center in Rotterdam in 1991. He presented his thesis ‘The Role of Somatostatin Receptors in Breast and Pancreatic Cancer’ in 1993. He is working at the Erasmus Medical Center and specializes in endocrine and pancreatobiliary surgery. He became Professor in Surgery in 2009.

References

Gastrointestinal Function after Pancreatoduodenectomy

Pancreatoduodenectomy

Gastrointestinal Function after Pancreatoduodenectomy

Panreatoduodenectomy


